Bristol-Myers Opdivo, Yervoy show promise in lung cancer trial
Bristol-Myers Squibb said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.
New Delhi: Bristol-Myers Squibb Co said on Tuesday an interim analysis of a late-stage trial testing a combination of its immuno-oncology drugs Opdivo and Yervoy met the main goal of extending the life of previously untreated lung cancer patients.
Shares of the company rose 5% to $56 in premarket trading.
The company said its therapies when administered alongside two courses of chemotherapy demonstrated superior overall survival compared to chemotherapy alone in patients with advanced non-small cell lung cancer, the most common form of the disease.
Data presented at a medical meeting last month showed that about 40% of patients with advanced lung cancer on the Opdivo-Yervoy combination were alive after two years, outperforming chemotherapy as a first-line treatment.
Read Also: Bristol Myers Squibb-Pfizer Alliance in collaboration with Fitbit to take on Apple Watch
Opdivo and Yervoy compete with rival drugs from companies such as Merck & Co and Roche in several types of cancer.
Merck's Keytruda dominates the highly lucrative market for newly diagnosed advanced lung cancer. Shares of the company fell 2.6% to $82.30 following the Bristol-Myers news.
The interim analysis builds on the positive results the Opdivo-Yervoy combination has previously shown in melanoma and renal cell carcinoma, said Bristol-Myers, adding that it will present full data from the trial at an upcoming meeting.
Read Also: Bristol-Myers CEO says Japan restrictive drug price policies risk diverting investment
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at email@example.com. Check out more about our bureau/team here